Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shwu-Jiuan Sheu, Cheng-Kuo Cheng, Hsi-Kung Kuo, Ching-Yao Tsai, Tai-Chi Lin, Jonathan Tan, Hitesh Chandwani, Michael Adena & Shih-Jen Chen. (2018) Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review. Clinical Ophthalmology 12, pages 2189-2198.
Read now
Read now
Nguyen Tu Dang Le, Luyen Dinh Pham & Trung Quang Vo. (2017) Type 2 diabetes in Vietnam: a cross-sectional, prevalence-based cost-of-illness study. Diabetes, Metabolic Syndrome and Obesity 10, pages 363-374.
Read now
Read now
Szilárd Kiss, Hitesh S Chandwani, Ashley L Cole, Vaishali D Patel, Orsolya E Lunacsek & Pravin U Dugel. (2016) Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clinical Ophthalmology 10, pages 2443-2453.
Read now
Read now
Sobha Sivaprasad & Sesan Oyetunde. (2016) Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clinical Ophthalmology 10, pages 939-946.
Read now
Read now
Richard A. Brook, Nathan L. Kleinman, Sunil Patel, Jim E. Smeeding, Ian A. Beren & Adam Turpcu. (2015) United States comparative costs and absenteeism of diabetic ophthalmic conditions. Postgraduate Medicine 127:5, pages 455-462.
Read now
Read now
Er Chen, Mark Looman, Marianne Laouri, Meghan Gallagher, Karen Van Nuys, Darius Lakdawalla & Joan Fortuny. (2010) Burden of illness of diabetic macular edema: literature review. Current Medical Research and Opinion 26:7, pages 1587-1597.
Read now
Read now
Articles from other publishers (39)
Simon KH. Szeto, Timothy YY. Lai, Stela Vujosevic, Jennifer K. Sun, SriniVas R. Sadda, Gavin Tan, Sobha Sivaprasad, Tien Y. Wong & Carol Y. Cheung. (2023) Optical coherence tomography in the management of diabetic macular oedema. Progress in Retinal and Eye Research, pages 101220.
Crossref
Crossref
Tina Felfeli, Glen Katsnelson, Alex Kiss, Lesley Plumptre, J. Michael Paterson, Brian G. Ballios, Efrem D. Mandelcorn, Richard H. Glazier, Michael H. Brent & David T. Wong. (2023) Prevalence and predictors for being unscreened for diabetic retinopathy: a population-based study over a decade. Canadian Journal of Ophthalmology 58:4, pages 278-286.
Crossref
Crossref
Karen Mulligan, Jaehong Kim, Bryan Tysinger, Jill Blim, Geoffrey Emerson, Philip J. Ferrone, Judy E. Kim, Seth Seabury & Paul Hahn. (2023) The Broader Economic Value of Treatment for Diabetic Macular Edema. Diabetes Care 46:6, pages 1196-1203.
Crossref
Crossref
Stuart Redding, Robert Anderson, Rajiv Raman, Sobha Sivaprasad & Raphael Wittenberg. (2023) Estimating the costs of blindness and moderate to severe visual impairment among people with diabetes in India. BMJ Open 13:6, pages e063390.
Crossref
Crossref
Grant L. Hom, Thomas B. Cwalina, Tarun K. Jella & Rishi P. Singh. (2021) Assessing financial insecurity among common eye conditions: a 2016–2017 national health survey study. Eye 36:10, pages 2044-2051.
Crossref
Crossref
Mikkel S. Thagaard, Anna S. Vergmann & Jakob Grauslund. (2021) Topical treatment of diabetic retinopathy: a systematic review. Acta Ophthalmologica 100:2, pages 136-147.
Crossref
Crossref
Brian J. Petersen, Walter T. Linde-Zwirble, Tze-Woei Tan, Gary M. Rothenberg, Simon J. Salgado, Jonathan D. Bloom & David G. Armstrong. (2022) Higher rates of all-cause mortality and resource utilization during episodes-of-care for diabetic foot ulceration. Diabetes Research and Clinical Practice 184, pages 109182.
Crossref
Crossref
Jing Cao, Kun You, Kai Jin, Lixia Lou, Yao Wang, Menglu Chen, Xiangji Pan, Ji Shao, Zhaoan Su, Jian Wu & Juan Ye. (2020) Prediction of response to anti‐vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography‐based machine learning method. Acta Ophthalmologica 99:1.
Crossref
Crossref
William S. Gange, Benjamin Y. Xu, Khristina Lung, Brian C. Toy & Seth A. Seabury. (2021) Rates of Eye Care and Diabetic Eye Disease among Insured Patients with Newly Diagnosed Type 2 Diabetes. Ophthalmology Retina 5:2, pages 160-168.
Crossref
Crossref
Andrea Orji, PadmajaK Rani, Raja Narayanan, NirojK Sahoo & Taraprasad Das. (2021) The economic burden of diabetic retinopathy care at a tertiary eye care center in South India. Indian Journal of Ophthalmology 69:3, pages 666.
Crossref
Crossref
Ha-Lim Jeon, Hyesung Lee, Dongwon Yoon, Yeonkyung Lee, Jae Hui Kim, Donghyun Jee & Ju-Young Shin. (2020) Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis. BMJ Open 10:12, pages e042484.
Crossref
Crossref
Mingming Ma, Yupeng Xu, Shuyu Xiong, Jian Zhang, Qing Gu, Bilian Ke & Xun Xu. (2018) Involvement of ciliary neurotrophic factor in early diabetic retinal neuropathy in streptozotocin-induced diabetic rats. Eye 32:9, pages 1463-1471.
Crossref
Crossref
C. Hernández, A. Simó-Servat, P. Bogdanov & R. Simó. (2017) Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. Journal of Endocrinological Investigation 40:9, pages 925-935.
Crossref
Crossref
Xiao Zhang, Serena Low, Neelam Kumari, Jiexun Wang, Keven Ang, Darren Yeo, Chee Chew Yip, Subramaniam Tavintharan, Chee Fang Sum & Su Chi Lim. (2017) Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore. PLOS ONE 12:7, pages e0180949.
Crossref
Crossref
Joana Tavares Ferreira, Rita Proença, Marta Alves, Arnaldo Dias-Santos, Bruno Oliveira Santos, João Paulo Cunha, Ana Luísa Papoila & Luís Abegão Pinto. (2017) Retina and Choroid of Diabetic Patients Without Observed Retinal Vascular Changes: A Longitudinal Study. American Journal of Ophthalmology 176, pages 15-25.
Crossref
Crossref
Solène Schirr-Bonnans, Nadège Costa, Hélène Derumeaux-Burel, Jérémy Bos, Benoît Lepage, Valérie Garnault, Jacques Martini, Hélène Hanaire, Marie-Christine Turnin & Laurent Molinier. (2016) Cost of diabetic eye, renal and foot complications: a methodological review. The European Journal of Health Economics 18:3, pages 293-312.
Crossref
Crossref
Michael W. StewartMichael W. Stewart. 2017. Diabetic Retinopathy. Diabetic Retinopathy
257
268
.
Georgia Kourlaba, John Relakis, Ronan Mahon, Maria Kalogeropoulou, Georgia Pantelopoulou, Olga Kousidou & Nikos Maniadakis. (2016) Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost Effectiveness and Resource Allocation 14:1.
Crossref
Crossref
Elena Nicod, Timothy L. Jackson, Federico Grimaccia, Aris Angelis, Marc Costen, Richard Haynes, Edward Hughes, Edward Pringle, Hadi Zambarakji & Panos Kanavos. (2015) Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. The European Journal of Health Economics 17:8, pages 991-999.
Crossref
Crossref
Haruhisa Fukuda, Shunya Ikeda, Takeru Shiroiwa & Takashi Fukuda. (2016) The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan. PharmacoEconomics 34:10, pages 1005-1014.
Crossref
Crossref
Antony Clark, Jonathon Q. Ng, Nigel Morlet & James B. Semmens. (2016) Big data and ophthalmic research. Survey of Ophthalmology 61:4, pages 443-465.
Crossref
Crossref
M.J. Abraldes, A. Pareja & M. Roura. (2016) Analysis of costs associated with the management and morbidity of diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Archivos de la Sociedad Española de Oftalmología (English Edition) 91:6, pages 273-280.
Crossref
Crossref
M.J. Abraldes, A. Pareja & M. Roura. (2016) Análisis de los costes asociados al manejo y morbilidad del edema macular diabético y el edema macular secundario a oclusión venosa de la retina. Archivos de la Sociedad Española de Oftalmología 91:6, pages 273-280.
Crossref
Crossref
Mukoso N. Ozieh, Kinfe G. Bishu, Clara E. Dismuke & Leonard E. Egede. (2015) Trends in Health Care Expenditure in U.S. Adults With Diabetes: 2002–2011. Diabetes Care 38:10, pages 1844-1851.
Crossref
Crossref
Rafael Simó, Olga Simó-Servat & Cristina Hernández. (2015) Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?. Current Diabetes Reports 15:5.
Crossref
Crossref
Timothy M. Dall, Wenya Yang, Pragna Halder, Bo Pang, Marjan Massoudi, Neil Wintfeld, April P. Semilla, Jerry Franz & Paul F. Hogan. (2014) The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes. Diabetes Care 37:12, pages 3172-3179.
Crossref
Crossref
Quinn Tate, Amanda Fujiki, Kirsten Johnson & Matthew M. Wells. (2014) Novel smartphone attachment for ophthalmic and otoscopic exams. Novel smartphone attachment for ophthalmic and otoscopic exams.
Michael W. Stewart. (2014) Anti-VEGF Therapy for Diabetic Macular Edema. Current Diabetes Reports 14:8.
Crossref
Crossref
Cristina Hernández, Olga Simó-Servat & Rafael Simó. (2014) Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine 46:2, pages 209-214.
Crossref
Crossref
John R. Gonder, Valery M. Walker, Martin Barbeau, Nancy Zaour, Bryan H. Zachau, James R. Hartje & Ruihong Li. (2014) Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY). Journal of Ophthalmology 2014, pages 1-9.
Crossref
Crossref
Rafael Simó & Cristina Hernández. (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends in Endocrinology & Metabolism 25:1, pages 23-33.
Crossref
Crossref
Daniel A. Ollendorf, Jennifer A. Colby & Steven D. Pearson. (2013) COMPARATIVE EFFECTIVENESS OF ANTI-VEGF AGENTS FOR DIABETIC MACULAR EDEMA. International Journal of Technology Assessment in Health Care 29:4, pages 392-401.
Crossref
Crossref
. (2013) Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care 36:4, pages 1033-1046.
Crossref
Crossref
Andreea Ciudin, Cristina Hernández & Rafael Simó. (2013) Molecular Implications of the PPARs in the Diabetic Eye. PPAR Research 2013, pages 1-11.
Crossref
Crossref
Jasmina I. Ivanova, Howard G. Birnbaum, Evan Kantor, Matt Schiller & Ralph W. Swindle. (2012) Duloxetine Use in Chronic Low Back Pain. PharmacoEconomics 30:7, pages 595-609.
Crossref
Crossref
Jasmina I. Ivanova, Howard G. Birnbaum, Yohanne Kidolezi, Ying Qiu, David Mallett & Sue Caleo. (2010) Economic Burden of Epilepsy among the Privately Insured in the US. PharmacoEconomics 28:8, pages 675-685.
Crossref
Crossref
Jasmina I. Ivanova, Howard G. Birnbaum, Yohanne Kidolezi, Ying Qiu, David Mallett & Sue Caleo. (2010) Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 51:5, pages 838-844.
Crossref
Crossref
Lauren J. Lee, Andrew P. Yu, Scott J. Johnson, Howard G. Birnbaum, Pavel Atanasov, Don P. Buesching, Jeffrey A. Jackson & Jaime A. Davidson. (2010) Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysis. Diabetes Research and Clinical Practice 87:1, pages 108-116.
Crossref
Crossref
Leorey N. Saligan. (2008) Preventing Diabetic Retinopathy in Primary Care. The Nurse Practitioner 33:10, pages 46-47.
Crossref
Crossref